The point-of-care molecular diagnostics market size has grown rapidly in recent years. It will grow from $3.98 billion in 2025 to $4.58 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, expansion of emergency diagnostic testing, rising demand for rapid clinical decision support, improvements in molecular assay technologies, growing use of poc diagnostics in hospitals.
The point-of-care molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.91 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing adoption of home-based molecular testing, rising investments in rapid diagnostics infrastructure, expansion of respiratory and oncology testing applications, growing integration of cloud-based diagnostic platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of rapid molecular testing platforms, rising demand for decentralized diagnostic solutions, growing integration of automated sample processing, expansion of syndromic testing panels, enhanced focus on fast turnaround times.
The rapid increase in the prevalence of infectious and respiratory diseases is anticipated to play a significant role in supporting the growth of the point-of-care molecular diagnostics market. Respiratory infections, caused by viral or bacterial pathogens, affect the respiratory system and are commonly transmitted through coughing, sneezing, or direct physical contact. The management of these conditions involves a wide range of therapeutic approaches, including inhalers, oral drugs, intravenous therapies, and point-of-care molecular diagnostic solutions that support timely and accurate treatment. For example, in June 2024, according to the UK Health Security Agency, between week 40 of 2022 and week 15 of 2023, a total of 108 National Health Service trusts in England reported 1,681 critical care admissions linked to confirmed influenza cases. This represented a sharp rise compared with the previous season, which recorded 182 admissions across 114 trusts, increasing to 316 by week 39 of 2022. Therefore, the growing incidence of infectious and respiratory diseases, along with associated mortality risks, is driving demand for point-of-care molecular diagnostic solutions.
Major companies operating in the point-of-care molecular diagnostics market are concentrating on delivering technologically advanced solutions to reinforce their competitive positioning. These players are adopting next-generation point-of-care molecular diagnostic technologies and associated services, including enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), in situ hybridization, spectral karyotyping imaging, DNA microarrays, and related techniques, for integration into point-of-care devices with the objective of reducing analysis time and lowering overall costs. For example, in May 2023, Sensible Diagnostics, a United States-based diagnostics company, introduced a 10-minute point-of-care PCR system. The company is leveraging the expertise gained by Curative through its diagnostics operations during the COVID-19 pandemic. Sensible Diagnostics reported that it has conducted more than two million molecular point-of-care COVID-19 tests, and its PCR platform delivers results within a 10-minute timeframe.
In July 2024, Roche Holding AG, a Switzerland-based global healthcare company focused on developing medicines, treatments, and diagnostics, acquired LumiraDx Ltd. for an undisclosed amount. This acquisition is intended to enhance Roche Holding AG's diagnostics portfolio, improve access to decentralized healthcare solutions, and expand testing capabilities, especially in underserved regions. LumiraDx Ltd. is a UK-based diagnostic company that specializes in creating innovative point-of-care (POC) testing solutions.
Major companies operating in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, BioMérieux SA, Hologic Inc, Becton Dickinson and Company, Siemens Healthineers AG, QuidelOrtho Corporation, Bio Rad Laboratories Inc, Qiagen N V, Biocartis Group NV, DiaSorin S p A, SD Biosensor Inc, Cue Health Inc, Visby Medical Inc, Binx Health Inc, Molbio Diagnostics Pvt Ltd, Credo Diagnostics Biomedical Pvt Ltd, Genetron Health, Mammoth Biosciences Inc, Seegene Inc.
North America was the largest region in the point-of-care molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point-of-care molecular diagnostics market by increasing costs of imported reagents, microfluidic cartridges, analyzers, sensors, and semiconductor components. Healthcare systems in North America and Europe are most affected due to dependence on imported diagnostic hardware, while Asia-Pacific faces higher production costs for export-oriented devices. These tariffs are raising test prices and influencing procurement decisions. However, they are also driving domestic manufacturing, regional reagent production, and localized development of cost-efficient POC molecular diagnostic platforms.
The point-of-care molecular diagnostics market research report is one of a series of new reports that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point-of-care (POC) molecular diagnostics are tests designed to detect specific nucleic acids in clinical specimens, including feces, saliva, urine, blood, and tissue. These diagnostics rely on identifying targeted portions of microbial genetic material, specifically DNA or RNA. Widely utilized in the healthcare sector, POC molecular diagnostics are granted emergency usage authorization to diagnose various diseases. These diagnostics are instrumental in detecting disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS).
The primary products and services in point-of-care molecular diagnostics include assays and kits, instruments and analyzers, and software and services. Assays and kits are equipment used to carry out analyses, especially in studying disease pathways. They are commonly employed for rapid and accurate diagnosis and monitoring of various diseases. Technologies such as reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, and sequencing are utilized in POC molecular diagnostics for diagnosing diseases like respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis, and hematology. Point-of-care molecular diagnostics are employed in decentralized labs, hospitals, home care, and assisted living healthcare facilities.
The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The point-of-care molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.91 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing adoption of home-based molecular testing, rising investments in rapid diagnostics infrastructure, expansion of respiratory and oncology testing applications, growing integration of cloud-based diagnostic platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of rapid molecular testing platforms, rising demand for decentralized diagnostic solutions, growing integration of automated sample processing, expansion of syndromic testing panels, enhanced focus on fast turnaround times.
The rapid increase in the prevalence of infectious and respiratory diseases is anticipated to play a significant role in supporting the growth of the point-of-care molecular diagnostics market. Respiratory infections, caused by viral or bacterial pathogens, affect the respiratory system and are commonly transmitted through coughing, sneezing, or direct physical contact. The management of these conditions involves a wide range of therapeutic approaches, including inhalers, oral drugs, intravenous therapies, and point-of-care molecular diagnostic solutions that support timely and accurate treatment. For example, in June 2024, according to the UK Health Security Agency, between week 40 of 2022 and week 15 of 2023, a total of 108 National Health Service trusts in England reported 1,681 critical care admissions linked to confirmed influenza cases. This represented a sharp rise compared with the previous season, which recorded 182 admissions across 114 trusts, increasing to 316 by week 39 of 2022. Therefore, the growing incidence of infectious and respiratory diseases, along with associated mortality risks, is driving demand for point-of-care molecular diagnostic solutions.
Major companies operating in the point-of-care molecular diagnostics market are concentrating on delivering technologically advanced solutions to reinforce their competitive positioning. These players are adopting next-generation point-of-care molecular diagnostic technologies and associated services, including enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), in situ hybridization, spectral karyotyping imaging, DNA microarrays, and related techniques, for integration into point-of-care devices with the objective of reducing analysis time and lowering overall costs. For example, in May 2023, Sensible Diagnostics, a United States-based diagnostics company, introduced a 10-minute point-of-care PCR system. The company is leveraging the expertise gained by Curative through its diagnostics operations during the COVID-19 pandemic. Sensible Diagnostics reported that it has conducted more than two million molecular point-of-care COVID-19 tests, and its PCR platform delivers results within a 10-minute timeframe.
In July 2024, Roche Holding AG, a Switzerland-based global healthcare company focused on developing medicines, treatments, and diagnostics, acquired LumiraDx Ltd. for an undisclosed amount. This acquisition is intended to enhance Roche Holding AG's diagnostics portfolio, improve access to decentralized healthcare solutions, and expand testing capabilities, especially in underserved regions. LumiraDx Ltd. is a UK-based diagnostic company that specializes in creating innovative point-of-care (POC) testing solutions.
Major companies operating in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, BioMérieux SA, Hologic Inc, Becton Dickinson and Company, Siemens Healthineers AG, QuidelOrtho Corporation, Bio Rad Laboratories Inc, Qiagen N V, Biocartis Group NV, DiaSorin S p A, SD Biosensor Inc, Cue Health Inc, Visby Medical Inc, Binx Health Inc, Molbio Diagnostics Pvt Ltd, Credo Diagnostics Biomedical Pvt Ltd, Genetron Health, Mammoth Biosciences Inc, Seegene Inc.
North America was the largest region in the point-of-care molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point-of-care molecular diagnostics market by increasing costs of imported reagents, microfluidic cartridges, analyzers, sensors, and semiconductor components. Healthcare systems in North America and Europe are most affected due to dependence on imported diagnostic hardware, while Asia-Pacific faces higher production costs for export-oriented devices. These tariffs are raising test prices and influencing procurement decisions. However, they are also driving domestic manufacturing, regional reagent production, and localized development of cost-efficient POC molecular diagnostic platforms.
The point-of-care molecular diagnostics market research report is one of a series of new reports that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point-of-care (POC) molecular diagnostics are tests designed to detect specific nucleic acids in clinical specimens, including feces, saliva, urine, blood, and tissue. These diagnostics rely on identifying targeted portions of microbial genetic material, specifically DNA or RNA. Widely utilized in the healthcare sector, POC molecular diagnostics are granted emergency usage authorization to diagnose various diseases. These diagnostics are instrumental in detecting disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS).
The primary products and services in point-of-care molecular diagnostics include assays and kits, instruments and analyzers, and software and services. Assays and kits are equipment used to carry out analyses, especially in studying disease pathways. They are commonly employed for rapid and accurate diagnosis and monitoring of various diseases. Technologies such as reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, and sequencing are utilized in POC molecular diagnostics for diagnosing diseases like respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis, and hematology. Point-of-care molecular diagnostics are employed in decentralized labs, hospitals, home care, and assisted living healthcare facilities.
The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Point-of-Care Molecular Diagnostics Market Characteristics
3. Point-of-Care Molecular Diagnostics Market Supply Chain Analysis
4. Global Point-of-Care Molecular Diagnostics Market Trends and Strategies
5. Point-of-Care Molecular Diagnostics Market Analysis of End Use Industries
7. Global Point-of-Care Molecular Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Point-of-Care Molecular Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Point-of-Care Molecular Diagnostics Market Segmentation
10. Point-of-Care Molecular Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Point-of-Care Molecular Diagnostics Market
12. China Point-of-Care Molecular Diagnostics Market
13. India Point-of-Care Molecular Diagnostics Market
14. Japan Point-of-Care Molecular Diagnostics Market
15. Australia Point-of-Care Molecular Diagnostics Market
16. Indonesia Point-of-Care Molecular Diagnostics Market
17. South Korea Point-of-Care Molecular Diagnostics Market
18. Taiwan Point-of-Care Molecular Diagnostics Market
19. South East Asia Point-of-Care Molecular Diagnostics Market
20. Western Europe Point-of-Care Molecular Diagnostics Market
21. UK Point-of-Care Molecular Diagnostics Market
22. Germany Point-of-Care Molecular Diagnostics Market
23. France Point-of-Care Molecular Diagnostics Market
24. Italy Point-of-Care Molecular Diagnostics Market
25. Spain Point-of-Care Molecular Diagnostics Market
26. Eastern Europe Point-of-Care Molecular Diagnostics Market
27. Russia Point-of-Care Molecular Diagnostics Market
28. North America Point-of-Care Molecular Diagnostics Market
29. USA Point-of-Care Molecular Diagnostics Market
30. Canada Point-of-Care Molecular Diagnostics Market
31. South America Point-of-Care Molecular Diagnostics Market
32. Brazil Point-of-Care Molecular Diagnostics Market
33. Middle East Point-of-Care Molecular Diagnostics Market
34. Africa Point-of-Care Molecular Diagnostics Market
36. Point-of-Care Molecular Diagnostics Market Competitive Landscape and Company Profiles
37. Point-of-Care Molecular Diagnostics Market Other Major and Innovative Companies
40. Point-of-Care Molecular Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Point-Of-Care Molecular Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses point-of-care molecular diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for point-of-care molecular diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care molecular diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Assays And Kits; Instruments And Analyzers2) By Application: Respiratory Infections; Gastrointestinal Infections; Sexually Transmitted Infections (STIs); Hospital-Acquired Infections (HAIs); Bloodstream and Sepsis-Related Infections
3) By End-User: Decentralized Labs; Hospitals; Home Care; Assisted Living Healthcare Facilities
Subsegments:
1) By Assays And Kits: Nucleic Acid Amplification Tests (NAATs); Rapid Diagnostic Tests; Molecular Detection Kits; Reagents And Consumables2) By Instruments And Analyzers: Microfluidic Devices; Point-of-Care Analyzers
Companies Mentioned: Abbott Laboratories; F Hoffmann La Roche Ltd; BioMérieux SA; Hologic Inc; Becton Dickinson and Company; Siemens Healthineers AG; QuidelOrtho Corporation; Bio Rad Laboratories Inc; Qiagen N V; Biocartis Group NV; DiaSorin S p A; SD Biosensor Inc; Cue Health Inc; Visby Medical Inc; Binx Health Inc; Molbio Diagnostics Pvt Ltd; Credo Diagnostics Biomedical Pvt Ltd; Genetron Health; Mammoth Biosciences Inc; Seegene Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Point-of-Care Molecular Diagnostics market report include:- Abbott Laboratories
- F Hoffmann La Roche Ltd
- BioMérieux SA
- Hologic Inc
- Becton Dickinson and Company
- Siemens Healthineers AG
- QuidelOrtho Corporation
- Bio Rad Laboratories Inc
- Qiagen N V
- Biocartis Group NV
- DiaSorin S p A
- SD Biosensor Inc
- Cue Health Inc
- Visby Medical Inc
- Binx Health Inc
- Molbio Diagnostics Pvt Ltd
- Credo Diagnostics Biomedical Pvt Ltd
- Genetron Health
- Mammoth Biosciences Inc
- Seegene Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.58 Billion |
| Forecasted Market Value ( USD | $ 7.91 Billion |
| Compound Annual Growth Rate | 14.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
